Literature DB >> 2219463

Ofloxacin and imipenem in the treatment of Mycobacterium fortuitum and Mycobacterium chelonae lung infections.

W W Yew1, S Y Kwan, P C Wong, J Lee.   

Abstract

Two patients with Mycobacterium fortuitum and one patient with Mycobacterium chelonae lung infections were treated with ofloxacin and imipenem respectively. Of the former two, one had underlying inactive pulmonary tuberculosis and bronchiectasis and the other had silicosis. The latter had severe underlying bronchiectasis also. The treatments were well tolerated and the patients responded well.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2219463     DOI： 10.1016/0041-3879(90)90009-w

Source DB:  PubMed          Journal:  Tubercle        ISSN： 0041-3879


  9 in total

1.  Management of opportunist mycobacterial infections: Joint Tuberculosis Committee Guidelines 1999. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society.

Authors: 
Journal:  Thorax       Date:  2000-03       Impact factor: 9.139

Review 2.  Recent changes in taxonomy and disease manifestations of the rapidly growing mycobacteria.

Authors:  R J Wallace
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

Review 3.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

4.  Susceptibilities of Mycobacterium fortuitum biovar. fortuitum and the two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid.

Authors:  R J Wallace; B A Brown; G O Onyi
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

Review 5.  Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria.

Authors:  Barbara A Brown-Elliott; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

6.  Mycobacteria as a cause of infective exacerbation in bronchiectasis.

Authors:  C H Chan; A K Ho; R C Chan; H Cheung; A F Cheng
Journal:  Postgrad Med J       Date:  1992-11       Impact factor: 2.401

7.  Postantibiotic effects of amikacin and ofloxacin on Mycobacterium fortuitum.

Authors:  S Y Tsui; W W Yew; M S Li; C Y Chan; A F Cheng
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

8.  Are the Newer Carbapenems of Any Value against Tuberculosis.

Authors:  Ximena Gonzalo; Francis Drobniewski
Journal:  Antibiotics (Basel)       Date:  2022-08-07

9.  Ertapenem and Faropenem against Mycobacterium tuberculosis: in vitro testing and comparison by macro and microdilution.

Authors:  Ximena Gonzalo; Giovanni Satta; Julio Ortiz Canseco; Timothy D McHugh; Francis Drobniewski
Journal:  BMC Microbiol       Date:  2020-08-31       Impact factor: 3.605
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.